Stock Movers
Stock Movers

Jun 9, 2026 · 7 min

WPP rallies as GSK rebuilds oncology and Monte Paschi draws bids

WPP Gains, GSK Falls, Monte Paschi Up

The episode connects advertising’s AI exposure, a major pharmaceutical acquisition, and Italy’s contested banking landscape.

3 key takeaways
  1. 1WPP’s shares surged after an analyst argued artificial intelligence poses less threat to advertising than feared.
  2. 2GSK agreed to acquire US biotech firm Nuvalent for $10.6 billion to strengthen its oncology portfolio.
  3. 3Monte dei Paschi remains at the center of an ongoing bidding war in Italy’s banking sector.

Don't miss

GSK’s $10.6 billion Nuvalent acquisition stands out as the clearest strategic bet, aimed at rebuilding the company’s oncology portfolio.

The brief

WPP’s stock surged after a positive analyst rating challenged the idea that artificial intelligence will severely disrupt the advertising sector.

GSK is pursuing a $10.6 billion acquisition of US biotech firm Nuvalent, using the deal to rebuild its oncology portfolio.

The episode also follows the ongoing bidding war for Italy’s Monte dei Paschi bank, where competing interest keeps the stock in focus.

Together, the stories show three distinct forces moving European shares: changing technology expectations, pharmaceutical dealmaking, and banking consolidation.

What was said on this episode

3 statements · 2 positive · 1 neutral

  1. Stephen Carrollon GSK acquisition of New ValentNeutral2:09

    GSK is buying New Valent for $10.6 billion.

    “buying a US biotech company called New Valent for $10.6 billion”

    Listen at 2:09

  2. Stephen Carrollon New Valent drugsPositive2:49

    New Valent drugs could become blockbuster medicines after approval.

    “the potential to become blockbuster medicines once approved”

    Listen at 2:49

  3. Stephen Carrollon GSK acquisition of New ValentPositive3:12

    The New Valent acquisition will probably boost GSK later.

    “it's probably going to be a boost for GSK down the line”

    Listen at 3:12

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.